Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination
Thorax ( IF 9.0 ) Pub Date : 2022-01-01 , DOI: 10.1136/thoraxjnl-2021-217985 Alison M DeDent 1 , Erica Farrand 2
Thorax ( IF 9.0 ) Pub Date : 2022-01-01 , DOI: 10.1136/thoraxjnl-2021-217985 Alison M DeDent 1 , Erica Farrand 2
Affiliation
After millions of deaths worldwide and months of widespread social and economic devastation, the first vaccine against SARS-CoV-2 (COVID-19) was given emergency use listing by the WHO.1 Approved only 1 year after the virus was first identified in Wuhan, China, this historic achievement was the result of public and private institutional partnerships, as well as decades of foundational scientific research. Two of the earliest vaccines authorised for widespread use were the BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) messenger RNA (mRNA) vaccines, demonstrating 95% and 94.1% efficacy, respectively, in phase II/III clinical trials. Notably, both vaccines have strong safety profiles, with the most common adverse events including injection site reactions, fever, chills, fatigue, headache, and muscle and joint aches.2 3 Postauthorisation reports of severe reactions, including anaphylaxis, have been extremely rare, occurring in only 4.5 reported cases per million doses.4 In this issue of Thorax , Park and colleagues5 present the first published case of COVID-19 vaccine-related interstitial lung disease (ILD). An 86-year-old man developed an acute onset of fever, weakness, shortness of breath and hypoxaemia requiring high-flow nasal cannula 1 day after receiving a dose of a COVID-19 mRNA vaccine. He had no history of ILD, connective tissue …
更新日期：2021-12-16
京公网安备 11010802027423号